Which applications of CRISPR technology will achieve regulatory approval for use in humans by 2030?
➕
Plus
15
Ṁ700
2031
53%
Targeting viral infections (e.g., HIV)
65%
Cancer treatment
30%
Anti-aging therapies
34%
Enhancing human physical abilities

Resolution criteria:

Approval from a recognized regulatory body, such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or equivalent organizations in other countries.

Categories:

  • Targeting Viral Infections: This category encompasses the use of CRISPR technology to edit human cells in a way that makes them resistant to infections by specific viruses, such as HIV.

  • Cancer treatment: Approval for therapies that use CRISPR to modify human cells to fight various forms of cancer, such as editing immune cells to target cancer cells more effectively.

  • Anti-aging therapies: Approval for treatments aimed at delaying the aging process or reversing age-related deterioration at the genetic level.

  • Enhancing human physical abilities: Approval for applications designed to enhance or improve human physical capabilities beyond the therapeutic treatment of disease, including but not limited to increased strength, endurance, or other physical traits.

Date: The first regulatory approval must be documented on or before December 31, 2030

Get
Ṁ1,000
and
S3.00
Sort by:

Does this market need a 'None of the above' option?

@GazDownright you can vote "No" for each of them

© Manifold Markets, Inc.Terms + Mana-only TermsPrivacyRules